Literature DB >> 32856462

Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers: A Comparison of Outcomes in Patients With COVID-19.

Ankur Kalra1,2, Edward S Hawkins3, Amy S Nowacki4, Vardhmaan Jain5, Alex Milinovich4, Joshua Saef1, George Thomas6, Surafel K Gebreselassie7, Sadashiva S Karnik8, Lara Jehi9, James B Young10, Lars G Svensson11, Mina K Chung1,8, Neil Mehta10.   

Abstract

Entities:  

Keywords:  COVID-19; mechanical ventilation; pandemic; propensity score; upregulation

Mesh：

Substances：

Year:  2020        PMID： 32856462      PMCID： PMC7578112          DOI： 10.1161/CIRCOUTCOMES.120.007115

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN： 1941-7713


× No keyword cloud information.
  8 in total

1.  Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans.

Authors:  B Hornig; C Kohler; H Drexler
Journal:  Circulation       Date:  1997-03-04       Impact factor: 29.690

Review 2.  Angiotensin II, tissue factor and the thrombotic paradox of hypertension.

Authors:  Alessandro Celi; Silvana Cianchetti; Giulia Dell'Omo; Roberto Pedrinelli
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-12

3.  Regulation of ACE2 in cardiac myocytes and fibroblasts.

Authors:  Patricia E Gallagher; Carlos M Ferrario; E Ann Tallant
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-10       Impact factor: 4.733

4.  Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats.

Authors:  I Hamming; H van Goor; A J Turner; C A Rushworth; A A Michaud; P Corvol; G Navis
Journal:  Exp Physiol       Date:  2008-01-11       Impact factor: 2.969

5.  Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.

Authors:  Giuseppe Mancia; Federico Rea; Monica Ludergnani; Giovanni Apolone; Giovanni Corrao
Journal:  N Engl J Med       Date:  2020-05-01       Impact factor: 91.245

6.  Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).

Authors:  Neil Mehta; Ankur Kalra; Amy S Nowacki; Scott Anjewierden; Zheyi Han; Pavan Bhat; Andres E Carmona-Rubio; Miriam Jacob; Gary W Procop; Susan Harrington; Alex Milinovich; Lars G Svensson; Lara Jehi; James B Young; Mina K Chung
Journal:  JAMA Cardiol       Date:  2020-09-01       Impact factor: 14.676

7.  COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia?

Authors:  Cheryl L Maier; Alexander D Truong; Sara C Auld; Derek M Polly; Christin-Lauren Tanksley; Alexander Duncan
Journal:  Lancet       Date:  2020-05-25       Impact factor: 79.321

8.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321
  8 in total
  2 in total

Review 1.  COVID-19: immunopathology, pathophysiological mechanisms, and treatment options.

Authors:  Larissa E van Eijk; Mathijs Binkhorst; Arno R Bourgonje; Annette K Offringa; Douwe J Mulder; Eelke M Bos; Nikola Kolundzic; Amaal E Abdulle; Peter Hj van der Voort; Marcel Gm Olde Rikkert; Johannes G van der Hoeven; Wilfred Fa den Dunnen; Jan-Luuk Hillebrands; Harry van Goor
Journal:  J Pathol       Date:  2021-03-25       Impact factor: 9.883

2.  The Interplay Between the Immune System, the Renin-Angiotensin-Aldosterone System (RAAS), and RAAS Inhibitors May Modulate the Outcome of COVID-19: A Systematic Review.

Authors:  Hiba Naveed; Abdallah Elshafeey; Dana Al-Ali; Emmad Janjua; Areej Nauman; Hussam Kawas; Ridhima Kaul; Arwa Saed Aldien; Mohamed B Elshazly; Dalia Zakaria
Journal:  J Clin Pharmacol       Date:  2021-04-07       Impact factor: 2.860
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.